Physician profile
Rick Conetta
NPI 1881774917
$1,891.09
in general payments reported to CMS, 2019-2025
10 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $450 · 2023: $178 · 2024: $300 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $872.05 | 2022-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $196.03 | 2022-2024 | Nucala |
| Olympus America INC. | $125.00 | 2022 | |
| Boston Scientific Corporation | $125.00 | 2019 | |
| Siemens Medical Solutions USA, INC. | $125.00 | 2025 | Cios Spin |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $124.64 | 2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2025 | Opsumit, Uptravi |
| Intuitive Surgical, INC. | $72.37 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Conetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.